BR112023019075A2 - Inibição de protease 1 específica de ubiquitina (usp1) - Google Patents

Inibição de protease 1 específica de ubiquitina (usp1)

Info

Publication number
BR112023019075A2
BR112023019075A2 BR112023019075A BR112023019075A BR112023019075A2 BR 112023019075 A2 BR112023019075 A2 BR 112023019075A2 BR 112023019075 A BR112023019075 A BR 112023019075A BR 112023019075 A BR112023019075 A BR 112023019075A BR 112023019075 A2 BR112023019075 A2 BR 112023019075A2
Authority
BR
Brazil
Prior art keywords
usp1
ubiquitin
inhibition
specific protease
compounds
Prior art date
Application number
BR112023019075A
Other languages
English (en)
Inventor
Joseph Buckmelter Alexandre
Loren Berry
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of BR112023019075A2 publication Critical patent/BR112023019075A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Detergent Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

inibição de protease 1 específica de ubiquitina (usp1). a presente invenção refere-se a compostos para a inibição de usp1, e aos métodos relacionados de preparação e uso dos compostos.
BR112023019075A 2021-04-07 2022-04-06 Inibição de protease 1 específica de ubiquitina (usp1) BR112023019075A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163171796P 2021-04-07 2021-04-07
PCT/US2022/023669 WO2022216820A1 (en) 2021-04-07 2022-04-06 Inhibiting ubiquitin-specific protease 1 (usp1)

Publications (1)

Publication Number Publication Date
BR112023019075A2 true BR112023019075A2 (pt) 2023-10-17

Family

ID=83546542

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023019075A BR112023019075A2 (pt) 2021-04-07 2022-04-06 Inibição de protease 1 específica de ubiquitina (usp1)

Country Status (10)

Country Link
EP (1) EP4319758A1 (pt)
JP (1) JP2024514322A (pt)
KR (1) KR20230167071A (pt)
CN (1) CN117241801A (pt)
AU (1) AU2022254062A1 (pt)
BR (1) BR112023019075A2 (pt)
CA (1) CA3214040A1 (pt)
CL (1) CL2023002956A1 (pt)
IL (1) IL307157A (pt)
WO (1) WO2022216820A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3235765A1 (en) 2021-11-12 2023-05-19 Jianping Wu Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
AU2022387669A1 (en) * 2021-11-12 2024-05-16 Insilico Medicine Ip Limited Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
AU2022384416A1 (en) * 2021-11-12 2024-05-16 Insilico Medicine Ip Limited Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
WO2023143424A1 (zh) * 2022-01-27 2023-08-03 四川海思科制药有限公司 一种氮杂并环衍生物及其在医药上的应用
WO2023148643A1 (en) * 2022-02-03 2023-08-10 Aurigene Oncology Limited Fused bicyclic heterocyclyl compounds as usp1 inhibitors
WO2023208130A1 (zh) * 2022-04-29 2023-11-02 江苏亚虹医药科技股份有限公司 嘧啶类化合物、其制备方法及其医药用途
CN117003757A (zh) * 2022-05-07 2023-11-07 苏州浦合医药科技有限公司 取代的双环杂芳基化合物作为usp1抑制剂
WO2024006879A1 (en) * 2022-06-29 2024-01-04 Zentaur Therapeutics Usa Inc. Usp1 inhibitors and uses thereof
WO2024022266A1 (en) * 2022-07-25 2024-02-01 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heteroaryl compounds as inhibitors of usp1
WO2024032647A1 (zh) * 2022-08-09 2024-02-15 上海济煜医药科技有限公司 含氮杂环化合物作为泛素-特异性蛋白酶1抑制剂的制备方法、应用及其用途
WO2024051795A1 (zh) * 2022-09-09 2024-03-14 正大天晴药业集团股份有限公司 用作泛素-特异性蛋白酶抑制剂的取代嘌呤酮衍生物
WO2024061213A1 (zh) * 2022-09-20 2024-03-28 正大天晴药业集团股份有限公司 用作泛素-特异性蛋白酶抑制剂的羰基稠合杂环衍生物
WO2024078436A1 (zh) * 2022-10-09 2024-04-18 海南先声再明医药股份有限公司 杂环并嘧啶类化合物、药物组合物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2797719C (en) * 2010-04-30 2019-11-26 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of usp1 deubiquitinating enzyme activity
EP2938610A2 (en) * 2012-12-28 2015-11-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
AU2016356694B2 (en) * 2015-11-20 2021-07-29 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
MX2021007179A (es) * 2018-12-20 2021-09-28 Ksq Therapeutics Inc Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora especifica de ubiquitina 1 (usp1).
EP3902802A4 (en) * 2018-12-28 2022-09-07 Forma Therapeutics, Inc. COMPOSITIONS FOR INHIBITING UBIQUITIN-SPECIFIC PROTEASE 1

Also Published As

Publication number Publication date
KR20230167071A (ko) 2023-12-07
JP2024514322A (ja) 2024-04-01
IL307157A (en) 2023-11-01
EP4319758A1 (en) 2024-02-14
CN117241801A (zh) 2023-12-15
WO2022216820A1 (en) 2022-10-13
AU2022254062A1 (en) 2023-10-12
CL2023002956A1 (es) 2024-03-08
CA3214040A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
BR112023019075A2 (pt) Inibição de protease 1 específica de ubiquitina (usp1)
BR112021024108A2 (pt) Inibidores de tead e usos dos mesmos
CL2022000751A1 (es) Inhibidores de la fosfatasa shp2 y métodos para su uso (divisional de la solicitud no. 202002419)
BR112017020900A2 (pt) compostos de 1-ciano-pirrolidina como inibidores de usp30
BR112022004451A2 (pt) Antagonistas de hpk1 e usos dos mesmos
CR20220351A (es) Inhibidores de proteínas kras mutantes
CL2021002882A1 (es) Inhibidores de fgfr y métodos de uso de los mismos
PH12021500013A1 (en) New heterocyclic compounds as monoacylgylcerol lipase inhibitors
BR112018017086A2 (pt) derivados de pirrolidina espiro-condensada como inibidores de enzimas desubiquitilantes (dub)
BR112019007977A2 (pt) composto, composição farmacêutica, método de tratamento ou prevenção de câncer, e, uso de um composto
CR9272A (es) Amino-imidazolonas para la inhibicion de b-secretasa
CR20210056A (es) Nuevos compuestos heterocíclicos como inhibidores de monoacilglicerol lipasa
DE602005010413D1 (de) Phosphonatanaloga von hiv-integrasehemmerverbindungen
BR112022011651A2 (pt) Degradadores de irak e usos dos mesmos
DOP2011000301A (es) Derivados de azaadamantano y metodos de uso de los mismos
BRPI0507052A (pt) inibidores de quìnase
MX2020008894A (es) Inhibidores de oxazin monoacilglicerol lipasa (magl).
CL2020003339A1 (es) Inhibidores de ectonucleotidasa y métodos de uso de los mismos
MX2022002711A (es) Nuevos inhibidores heterociclicos de monoacilglicerol lipasa (magl).
TW200613289A (en) Prodrugs of hiv protease inhibitors
BR112022003982A2 (pt) Compostos heterocíclicos
DOP2023000145A (es) Inhibidores de cdk2 y métodos de uso de los mismos
ECSP23019419A (es) Proceso e intermedios para preparar un inhibidor de jak1
ECSP22026478A (es) Inhibidor de diacilglicerol aciltransferasa 2
BR112022005895A2 (pt) Inibidores de aldose redutase para tratamento de deficiência de fosfomanomutase 2